Mold Illness and CIRS: The Functional Medicine Assessment Framework
Chronic Inflammatory Response Syndrome (CIRS) from water-damaged buildings affects an estimated 25% of genetically susceptible individuals exposed to mold. Here's the Shoemaker protocol, diagnostic framework, and evidence-based naturopathic support strategies.
This article is intended for healthcare practitioners and informed readers. It does not constitute medical advice or a diagnostic framework for self-treatment. Chronic Inflammatory Response Syndrome (CIRS) is a complex multi-system condition requiring assessment and management by a qualified physician familiar with biotoxin illness. If you suspect mold-related illness, seek professional evaluation before pursuing any treatment protocol.
Introduction: A Diagnosis the Mainstream Has Been Slow to Accept
Few conditions in integrative and environmental medicine have generated more clinical controversy — and more patient suffering — than Chronic Inflammatory Response Syndrome (CIRS) from water-damaged buildings. For patients: years of debilitating fatigue, cognitive impairment, chronic pain, and unexplained multi-system symptoms, cycling through specialist after specialist who find nothing definably wrong. For practitioners: a condition that does not fit neatly into conventional diagnostic boxes, supported by a body of research that is rigorous by functional medicine standards but remains contested in mainstream clinical settings.
The foundational work of Dr Ritchie Shoemaker — a Maryland physician who began identifying and treating biotoxin illness in patients exposed to Pfiesteria piscicida in the late 1990s — established the conceptual and clinical framework that still underpins CIRS assessment today. Shoemaker's contribution was to identify that a subset of patients exposed to water-damaged buildings (WDBs) develop a self-perpetuating inflammatory state that does not resolve with mold avoidance alone, and that this susceptibility is substantially determined by immune response genetics.
This article provides a practitioner-level overview of the CIRS framework: its biological basis, diagnostic approach, Shoemaker's sequential treatment protocol, and the evidence-based naturopathic interventions that can be used adjunctively within a medically supervised treatment plan. It also addresses the critical distinction between mycotoxins and the broader category of WDB biotoxins that drives CIRS — a distinction that matters considerably for both laboratory testing and treatment rationale.
What Is CIRS? The Biotoxin Illness Model
CIRS is defined as a multi-system, multi-symptom illness caused by exposure to the interior environment of a water-damaged building, in which the affected individual lacks the genetic capacity to efficiently clear certain classes of biotoxins. The name is descriptive: it is an inflammatory response syndrome that is chronic, and it is triggered by biotoxins — biological toxins produced by the microbial ecology of damp indoor environments.
The distinction from simple mold allergy is important. Classical mold allergy involves IgE-mediated hypersensitivity to mold spore proteins — a conventional immunological mechanism that can be confirmed by skin testing and managed with antihistamines and avoidance. CIRS is not an allergic condition. It is an innate immune dysregulation in which biotoxins — because they cannot be adequately cleared — bind to antigen-presenting cells, trigger sustained cytokine activation, and produce downstream inflammatory disruption across multiple organ systems: hypothalamic-pituitary function, the vascular endothelium, the complement cascade, neuropeptide signalling, and the peripheral nervous system.
The distinction also matters for prognosis. A patient with mold allergy who leaves the building will typically improve as allergen exposure ends. A patient with CIRS who leaves the building may initially improve but often does not fully recover, because the inflammatory dysregulation has become self-perpetuating. Shoemaker's observation — that biotoxin-susceptible patients did not reliably recover simply by relocating — was the clinical anomaly that prompted the development of his sequential treatment model.
The HLA-DR Susceptibility Gene: Why Not Everyone Gets Sick
Approximately 24% of the population carries HLA-DR immune response gene variants that impair their ability to recognise and present certain biotoxin antigens for immune clearance. This genetic susceptibility is the critical determining factor in who develops CIRS following WDB exposure.
The HLA system — the human leukocyte antigen complex on chromosome 6 — encodes the cell-surface proteins that present foreign antigens to T cells, enabling adaptive immune recognition and clearance. For most antigens, this process is efficient: the antigen is presented, T cells mount a targeted response, and the antigen is neutralised and cleared. For individuals with certain HLA-DR variants, specific biotoxins from WDB environments appear to slip past this recognition system. Without adequate immune recognition, the innate immune response remains persistently activated — not because the immune system is failing to react, but because it cannot mount the specific adaptive response needed to clear and extinguish the trigger.
This genetic framing explains several clinical features of CIRS that otherwise appear paradoxical: why two individuals can live in the same water-damaged building, with one becoming profoundly ill and the other remaining entirely healthy; why the illness persists and sometimes worsens after leaving the building; and why general anti-inflammatory approaches provide only partial and temporary relief. HLA-DR genotyping is part of the CIRS diagnostic workup and helps confirm susceptibility, though it is not diagnostic in isolation — the clinical picture, biomarker panel, and exposure history must all cohere.
Symptom Profile: A Multi-System Illness with Significant Diagnostic Overlap
CIRS produces a characteristic — though variable — symptom cluster that reflects its multi-system inflammatory pathophysiology. The most commonly reported symptoms include:
Neurological and cognitive: Brain fog, difficulty concentrating and word retrieval, memory impairment, disorientation, headaches, light sensitivity, and unusual visual symptoms including blurring and difficulty with contrast.
Fatigue and pain: Profound and disproportionate fatigue unresponsive to rest, widespread musculoskeletal aching, joint pain without inflammatory markers on standard testing, ice-pick headaches, and abdominal pain.
Autonomic and systemic: Unusual thirst and increased urination (related to ADH dysregulation), temperature dysregulation, excessive sweating or inability to sweat appropriately, numbness and tingling (particularly in the extremities), and palpitations.
Mood and psychiatric: Anxiety, irritability, depression, and emotional dysregulation — often severe enough to attract primary psychiatric diagnoses in patients whose underlying CIRS has not been identified.
Sinus and respiratory: Chronic sinus congestion, shortness of breath on exertion, and reactive airways symptoms.
The diagnostic challenge is substantial. This symptom profile overlaps significantly with fibromyalgia, ME/CFS, chronic Lyme disease, and major depressive disorder. Many CIRS patients receive one or more of these diagnoses before their WDB exposure history is taken seriously. The presence of multiple symptom clusters — particularly the combination of cognitive, autonomic, and musculoskeletal symptoms in someone with a history of WDB exposure — should prompt consideration of the CIRS framework.
Diagnostic Framework: A Multi-Layered Assessment
The CIRS diagnosis is not based on any single test. It is an integrative assessment combining exposure history, symptom patterns, objective screening tests, and a specific biomarker panel. All elements must be present and coherent.
Visual Contrast Sensitivity Testing
The Visual Contrast Sensitivity (VCS) test is Shoemaker's primary screening tool for biotoxin illness. VCS measures the eye's ability to distinguish contrast at low spatial frequencies — a neurological function mediated by the optic nerve and visual cortex. Biotoxin-mediated neurological inflammation impairs this pathway reproducibly. The test involves identifying gratings at progressively lower contrast levels; a standardised failure pattern is considered a positive screen for biotoxin illness.
VCS testing is not specific to CIRS — other neurological conditions can produce similar findings — but in the context of WDB exposure and a multi-symptom presentation, a positive VCS result substantially increases clinical probability. Shoemaker's online VCS test provides a validated, low-cost initial screen that practitioners can direct patients to before more expensive laboratory workup.
Blood Biomarker Panel
The CIRS biomarker panel assesses multiple inflammatory and regulatory pathways disrupted by biotoxin exposure:
TGF-beta1 (Transforming Growth Factor beta-1): Elevated in CIRS; a cytokine associated with inflammatory activation, fibrosis, and immune dysregulation. TGF-beta1 elevation correlates with symptom severity in many CIRS patients.
MMP-9 (Matrix Metalloproteinase-9): Elevated in CIRS; degrades extracellular matrix proteins and is implicated in blood-brain barrier disruption, contributing to neurological symptoms including brain fog and cognitive impairment.
VEGF (Vascular Endothelial Growth Factor): Dysregulated in CIRS — often low, reflecting vascular insufficiency and capillary dropout that contributes to the profound fatigue and exercise intolerance seen in affected patients.
MSH (Alpha-Melanocyte Stimulating Hormone): Characteristically low in CIRS. MSH is a key regulatory neuropeptide that modulates inflammation, pain sensitivity, sleep quality, and mucosal immunity. Its depletion is considered a central feature of the CIRS cascade and explains many of the neuropeptide-mediated symptoms including sleep disruption and heightened pain.
VIP (Vasoactive Intestinal Peptide): Also typically low in CIRS. VIP regulates pulmonary blood flow, autonomic function, and immune modulation. Depletion contributes to respiratory and autonomic symptoms that are otherwise difficult to explain on conventional investigation.
C3a and C4a (Complement Activation Split Products): C4a in particular is often markedly elevated in CIRS, reflecting chronic complement system activation — an innate immune pathway that Shoemaker identified as a key driver of the inflammatory cascade in biotoxin illness.
Leptin: Often elevated in CIRS, contributing to resistance to weight loss, fatigue, and hypothalamic dysregulation seen in many patients.
ADH and serum osmolality: ADH (antidiuretic hormone) dysregulation — often low ADH with compensatory elevated osmolality — explains the unusual thirst and polyuria that is a characteristic but frequently overlooked CIRS symptom.
HLA-DR Genotyping
HLA-DR genotyping is performed from a blood sample and identifies whether the patient carries one of the susceptibility genotypes associated with impaired biotoxin clearance. Shoemaker's work categorised these into dreamer types (at risk for CIRS) and multi-susceptible types (at risk for multiple biotoxin illnesses). While not all HLA-DR susceptible individuals who are exposed will develop CIRS, the finding of susceptibility in a symptomatic patient with WDB exposure significantly strengthens the diagnosis.
Mycotoxins vs WDB Biotoxins: A Critical Distinction
A common point of clinical confusion is the relationship between mycotoxins and the broader category of WDB biotoxins that drives CIRS. These are related but not equivalent categories.
Mycotoxins are toxic secondary metabolites produced specifically by fungi (molds). The most toxicologically significant mycotoxins in WDB environments include ochratoxin A (produced primarily by Aspergillus and Penicillium species), trichothecenes (produced by Stachybotrys chartarum among others), and aflatoxins (predominantly an agricultural concern but detectable in some indoor environments). Mycotoxins can be measured in urine via specialised laboratories, and urinary mycotoxin testing is used by some practitioners as part of the CIRS workup or as a standalone assessment.
WDB biotoxins is a broader category that encompasses mycotoxins but also includes bacterial endotoxins (particularly from gram-negative organisms and actinomycetes found in damp building materials), beta-glucans (fungal cell wall components that independently activate innate immune pathways), and the complex microbial volatile organic compounds generated by the collective microbial ecology of a water-damaged environment. Shoemaker's CIRS framework is explicitly built on this broader category — it is the total biotoxin burden from the WDB environment, not mycotoxins alone, that drives the CIRS cascade in susceptible individuals.
This distinction has practical implications. A patient may have a negative or borderline urinary mycotoxin panel but still have significant CIRS driven by bacterial endotoxins or other non-mycotoxin WDB biotoxins. Relying on urinary mycotoxins as the primary evidence of WDB illness can therefore produce false-negative conclusions in genuinely affected patients.
The Shoemaker Protocol: A Sequential Medical Treatment Framework
Shoemaker's treatment protocol is an 11-step sequential process, with each step dependent on completion of the preceding one. It is a medical protocol requiring physician supervision — particularly in the middle and later stages where prescription interventions are involved. Practitioners should have access to Shoemaker's published materials and training before implementing the full protocol.
The broad sequential logic is as follows:
Step 1 — Remove the exposure. This is non-negotiable and must precede all other treatment. No intervention will produce durable improvement in a patient who remains in the causative environment. This sounds obvious but is frequently the most difficult step clinically — many patients live or work in the WDB, have financial barriers to relocation, or genuinely cannot identify the source environment without professional testing.
Steps 2–4 — Binders. Cholestyramine (a prescription bile acid sequestrant) is Shoemaker's primary binder of choice, used to bind biotoxins in the gastrointestinal tract and interrupt enterohepatic recirculation. Welchol (colesevelam hydrochloride) is used as an alternative for patients who cannot tolerate cholestyramine. These are prescription medications with established clinical evidence in the CIRS context.
Subsequent steps address specific biomarker abnormalities in sequence: MMP-9 reduction, correction of ADH and osmolality dysregulation, and restoration of downstream neuropeptide deficits including MSH and VIP. VIP nasal spray — available via compounding pharmacy with appropriate prescription — is used in later protocol stages for patients who have completed the preceding steps and still carry residual VIP deficiency. The sequential nature of the protocol is intentional. Attempting to address later-stage biomarker deficiencies before removing exposure and initiating binder therapy is unlikely to produce durable benefit, because the upstream biotoxin burden continues to drive the inflammatory cascade that depletes these downstream regulators.
Naturopathic Adjunctive Support
Within a medically supervised CIRS management plan, several naturopathic interventions can provide meaningful adjunctive support. These are not substitutes for the Shoemaker protocol steps but can reduce symptom burden, support detoxification pathways, and address common comorbidities.
Adjunctive binders. Activated charcoal and bentonite clay are used by some practitioners as lower-potency binders. The evidence for their efficacy in CIRS specifically is far weaker than for cholestyramine — they have broader and less selective binding profiles and have not been studied in CIRS cohorts with comparable rigour. They are sometimes used in patients with mild presentations who are not yet working with a CIRS-trained physician, or as adjuncts to prescription binder therapy. All binders should be taken well away from meals and any medications, as they will bind nutrients and drugs non-selectively.
Glutathione support. Glutathione is the body's primary intracellular antioxidant and a key player in phase II hepatic biotoxin conjugation. Mycotoxin exposure depletes glutathione stores, and supporting glutathione synthesis — via N-acetylcysteine (NAC), liposomal glutathione, or precursor nutrients including glycine — is a reasonable adjunctive strategy with strong mechanistic rationale. NAC has an established safety profile and is widely used in integrative practice for both detoxification support and antioxidant repletion.
Liver support. The liver is the primary site of biotoxin phase I and phase II detoxification. Milk thistle (Silybum marianum, standardised to silymarin) has well-replicated hepatoprotective and antioxidant effects and is a rational adjunct during any detoxification protocol. Adequate hydration, regular bowel motility, and targeted B-vitamin support (particularly B2, B3, and B6 as cytochrome P450 cofactors) are further practical considerations that are frequently overlooked in complex protocols.
Addressing mast cell activation. Mast cell activation syndrome (MCAS) is a recognised and common comorbidity in CIRS patients. Biotoxin-driven inflammatory cytokines can trigger mast cell degranulation, producing histamine excess and an additional layer of symptomatology including urticaria, flushing, gastrointestinal cramping, and hypotension. Where MCAS is suspected, a low-histamine dietary approach and mast cell-stabilising nutrients — quercetin, vitamin C, and diamine oxidase (DAO) enzyme support — can reduce the reactive burden. For further detail on the MCAS-CIRS intersection, see Mast Cell Activation Syndrome: The MCAS Clinical Framework.
Mitochondrial support. Biotoxin illness produces substantial mitochondrial stress, consistent with the profound fatigue that characterises CIRS. Coenzyme Q10, D-ribose, magnesium malate, and B-vitamin cofactors can support mitochondrial energy production adjunctively. For a deeper treatment of the mitochondrial mechanisms relevant to chronic inflammatory illness, see Mitochondrial Dysfunction in Functional Medicine.
Heavy metal co-assessment. CIRS patients with significant hepatic biotoxin burden may also have impaired heavy metal clearance, as shared detoxification pathways become overwhelmed. Concurrent heavy metal accumulation can compound neurological and inflammatory symptoms. Assessment is appropriate in complex or treatment-resistant presentations. See Heavy Metal Toxicity and Functional Testing for the functional testing framework applicable in this context.
Environmental Remediation: Getting Out Is Essential — But Not Always Sufficient
No amount of naturopathic or medical intervention will produce durable recovery in a patient who remains exposed to the causative WDB environment. Identifying and remediating — or leaving — the causative building is the prerequisite to all other treatment.
ERMI testing (Environmental Relative Mouldiness Index) is a DNA-based dust testing methodology that analyses settled dust from the home or workplace for the presence and relative abundance of 36 mold species, comparing the result against a national reference database. An ERMI score above 2 is generally considered elevated; scores above 5 carry high likelihood of active WDB conditions. ERMI provides far more specific species identification than air sampling or visual inspection alone.
HERTSMI-2 (Health Effects Roster of Type-Specific Formers of Mycotoxins and Inflammagens, 2nd edition) is a subset scoring tool derived from the ERMI panel that focuses on the five most clinically significant species: Stachybotrys chartarum, Aspergillus penicillioides, Aspergillus versicolor, Chaetomium globosum, and Wallemia sebi. A HERTSMI-2 score below 11 is generally considered safe for most individuals, including those in CIRS recovery; scores above 15 indicate an environment likely to perpetuate illness in susceptible individuals.
Where remediation is indicated, it must be performed by certified mold remediators following established containment protocols (IICRC S520 standard). Incomplete or improper remediation — including the common error of painting over affected surfaces or using biocides without addressing the underlying moisture source — can produce a false sense of safety while leaving the biotoxin ecology largely intact.
Clinical Considerations and Scope of Practice
CIRS remains a diagnosis at the edge of mainstream medical recognition. Practitioners working in this space should be familiar with the evidence base — Shoemaker's peer-reviewed publications, the CIRS-WDB consensus criteria, and the biomarker validation literature — while maintaining appropriate humility about diagnostic certainty and remaining alert to conditions that can mimic the CIRS picture.
The most important naturopathic contributions in this clinical space are: taking the exposure history seriously (asking systematically about WDB history in any patient with unexplained multi-system illness); facilitating appropriate medical referral for patients who fit the clinical picture; and providing evidence-based adjunctive support within a broader coordinated care plan.
What naturopathic practitioners can offer, and what many CIRS patients genuinely need, is a clinician who takes the environmental context of illness seriously, integrates the full symptom picture rather than treating organ systems in isolation, and helps the patient navigate a diagnostic journey that conventional medicine has not yet fully mapped.
Summary
Chronic Inflammatory Response Syndrome from water-damaged buildings is a genuine, biologically grounded, and often disabling condition affecting approximately 24% of genetically susceptible individuals following WDB exposure. Its foundation is HLA-DR immune genetics, sustained innate immune activation from WDB biotoxins (including but not limited to mycotoxins), and a downstream cascade of biomarker dysregulation affecting complement, neuropeptide, vascular, and hypothalamic-pituitary systems.
Diagnosis requires coherent integration of exposure history, VCS screening, and a targeted blood biomarker panel. Treatment requires removal from exposure as a prerequisite, prescription binder therapy (cholestyramine or Welchol), and sequential correction of downstream biomarker abnormalities under physician supervision. Naturopathic adjunctive support — including binders, glutathione precursors, liver support, MCAS management, and mitochondrial nutrients — can meaningfully reduce symptom burden within a medically supervised framework.
For patients who have cycled through diagnoses of fibromyalgia, ME/CFS, anxiety disorder, or medically unexplained illness, a thorough CIRS assessment offers a biologically coherent explanation and a structured, evidence-informed path toward recovery.